CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The TIGER project aims to validate a novel mRNA cancer vaccine platform designed for intravenous administration. It focuses on treating HPV16 positive cancers by enhancing immune responses using lipid nanoparticles to deliver therapeutic mRNAs effectively.
TIGER delivers proof of principle (PoP) in humans for a novel best-in-class therapeutic mRNA cancer vaccine platform optimized for intravenous (IV) administration, with the aim to show clinical benefit.
The antigens used for the PoP consists of mRNAs encoding the proteins E6 and E7 of Human Papilloma Virus strain 16 (HPV16), and TriMix mRNAs that act as adjuvant to stimulate dendritic cells to start strong T cell responses.
The mRNAs will be formulated in a novel patented lipid nanoparticle shie…
ETHERNA IMMUNOTHERAPIES
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Sweden, Lund
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Netherlands, Amsterdam
Type: Research institute
Activity type: Research Organisations
SME: No
CLINIQUES UNIVERSITAIRES SAINT-LUC ASBL
Belgium, Bruxelles / Brussel
Type: Other
Activity type: Other
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
